 It will be conducted in the Clinical Research Unit CRU of the Oxford Centre for Diabetes, Endocrinology and Metabolism OCDEM at the Churchill Hospital, Oxford. The aim is to find the dose of glibenclamide that causes a reduction in fasting glucagon levels in patients with T2DM. 